Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LPAR5 | Q9H1C0 | 6/20 | 0.97 |
| ▸ | LPAR1 | Q92633 | 13/20 | 0.67 |
| ▸ | LPAR3 | Q9UBY5 | 10/20 | 0.67 |
| ▸ | LPAR2 | Q9HBW0 | 7/20 | 0.59 |
| ▸ | LPAR4 | Q99677 | 5/20 | 0.59 |
| ▸ | LPAR6 | P43657 | 4/20 | 0.59 |
| ▸ | ENPP2 | Q13822 | 3/20 | 0.59 |
| ▸ | USP2 | O75604 | 1/20 | 0.56 |
| ▸ | HTT | P42858 | 1/20 | 0.54 |
| ▸ | P2RY10 | O00398 | 1/20 | 0.54 |
| ▸ | CES2 | O00748 | 1/20 | 0.51 |
| ▸ | TRPV1 | Q8NER1 | 1/20 | 0.51 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.48 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.48 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL45056 | 1.00 | LPAR5 (0.97) | LPAR5LPAR1LPAR3LPAR2LPAR4 | |
| SCHEMBL258161 | 0.98 | LPAR5 (1.00) | LPAR5LPAR1LPAR3LPAR2LPAR4 | |
| SCHEMBL7820593 | 0.98 | LPAR5 (1.00) | LPAR5LPAR1LPAR3LPAR2LPAR4 | |
| SCHEMBL258032 | 0.98 | LPAR5 (1.00) | LPAR5LPAR1LPAR3LPAR2LPAR4 | |
| SCHEMBL258118 | 0.98 | LPAR5 (1.00) | LPAR5LPAR1LPAR3LPAR2LPAR4 | |
| SCHEMBL7829804 | 0.98 | LPAR5 (1.00) | LPAR5LPAR1LPAR3LPAR2LPAR4 | |
| SCHEMBL12621099 | 0.98 | LPAR5 (1.00) | LPAR5LPAR1LPAR3LPAR2LPAR4 | |
| SCHEMBL258094 | 0.98 | LPAR5 (1.00) | LPAR5LPAR1LPAR3LPAR2LPAR4 | |
| SCHEMBL28064781 | 0.98 | LPAR5 (1.00) | LPAR5LPAR1LPAR3LPAR2LPAR4 | |
| SCHEMBL26603866 | 0.98 | LPAR5 (1.00) | LPAR5LPAR1LPAR3LPAR2LPAR4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 403 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4031685-B1 | IN VITRO FERTILISATION (IVF) EMBRYO VIABILILITY AND QUALITY ASSAY | UNIV TARTU (EE) | 2024-07-10 | — | — | EP | claimed |
| WO-2019182440-A1 | METHOD FOR PRODUCING CELL WALL-TARGETING ANTIBIOTICS IN SUSCEPTIBLE BACTERIA | TECHNISCHE UNIVERSTITEIT DELFT (NL) | 2019-09-26 | — | — | WO | claimed |
| WO-2011034263-A1 | METHOD FOR PREDICTING A DRUG TARGET IN PATHOGENIC MICROORGANISMS USING AN ESSENTIAL METABOLITE | 한국과학기술원 (KR) | 2011-03-24 | — | — | WO | claimed |
| WO-2011034397-A2 | METHOD FOR PREDICTING DRUG TARGETS AND SCREENING FOR DRUGS FOR PATHOGENIC MICROORGANISMS USING ESSENTIAL METABOLITES | 한국과학기술원 (KR) | 2011-03-24 | — | — | WO | claimed |
| JP-4301571-B2 | — | — | 2009-07-22 | — | — | JP | claimed |
| US-20070123492-A1 | Analogs of lysophosphatidic acid and methods of making and using thereof | NATIONAL INSTITUTES OF HEALTH - DIRECTOR DEITR | 2007-05-31 | — | — | US | claimed |
| EP-1615937-A2 | ANALOGS OF LYSOPHOSPHATIDIC ACID AND METHODS OF MAKING AND USING THEREOF | University of Utah Research Foundation (US) | 2006-01-18 | — | — | EP | claimed |
| WO-2004092188-A2 | ANALOGS OF LYSOPHOSPHATIDIC ACID AND METHODS OF MAKING AND USING THEREOF | UNIVERSITY OF UTAH RESEARCH FOUNDATION (US) | 2004-10-28 | — | — | WO | claimed |
| EP-0917580-A1 | DEFORMYLATION OF f-MET PEPTIDES IN BACTERIAL EXPRESSION SYSTEMS | MONSANTO COMPANY (US) | 1999-05-26 | — | — | EP | claimed |
| EP-0837630-A4 | PRODRUGS OF PHARMACEUTICALS WITH IMPROVED BIOAVAILABILITY | UNIV CALIFORNIA (US) | 1998-11-25 | — | — | EP | claimed |
| EP-0837630-A1 | PRODRUGS OF PHARMACEUTICALS WITH IMPROVED BIOAVAILABILITY | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 1998-04-29 | — | — | EP | claimed |
| WO-1998003664-A1 | DEFORMYLATION OF f-MET PEPTIDES IN BACTERIAL EXPRESSION SYSTEMS | MONSANTO COMPANY (US) | 1998-01-29 | — | — | WO | claimed |
| WO-1996039831-A1 | PRODRUGS OF PHARMACEUTICALS WITH IMPROVED BIOAVAILABILITY | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 1996-12-19 | — | — | WO | claimed |
| US-5411947-A | converting drugs having suitable functional groups to 1-O-alkyl-, 1-O-acyl-, 1-S-acyl, and 1-S-alkyl-sn-glycero-3-phosphate derivatives; drugs such as AZT, cladribine, AICA-Riboside | VESTAR, INC. (US) | 1995-05-02 | — | — | US | claimed |
| US-12631643-B2 | Tissue-derived extracellular vesicles and their use as diagnostics | EXOCURE SWEDEN AB (SE) | 2026-05-19 | — | — | US | disclosed |
| US-12600978-B2 | Process for producing lipids | Nuseed Global Innovation Ltd. (GB) | 2026-04-14 | — | — | US | disclosed |
| US-12516083-B2 | Nucleophilic catalysts for oxime linkage | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2026-01-06 | — | — | US | disclosed |
| EP-0673424-A1 | DNA ENCODING 2-ACYLTRANSFERASES | NICKERSON BIOCEM LIMITED (GB) | 1995-09-27 | — | — | EP | disclosed |
| US-5411947-A | converting drugs having suitable functional groups to 1-O-alkyl-, 1-O-acyl-, 1-S-acyl, and 1-S-alkyl-sn-glycero-3-phosphate derivatives; drugs such as AZT, cladribine, AICA-Riboside | VESTAR, INC. (US) | 1995-05-02 | — | — | US | disclosed |
| WO-1994013814-A1 | DNA ENCODING 2-ACYLTRANSFERASES | NICKERSON BIOCEM LIMITED (GB) | 1994-06-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12600978-B2 | Process for producing lipids | DGAT1, DGAT2, SOAT2 | LPAR5 203/4885LPAR1 110/4885LPAR3 171/4885 |
| US-20070123492-A1 | Analogs of lysophosphatidic acid and methods of making and using thereof | LPAR4, LPAR2, LPAR5 | LPAR5 3/4885LPAR1 6/4885LPAR3 7/4885 |
| US-12631643-B2 | Tissue-derived extracellular vesicles and their use as diagnostics | DNASE1, RNASE1, DNASE1L3 | LPAR5 2096/4885LPAR1 2493/4885LPAR3 2476/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.